NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory and pharma services company that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics. Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US. NeoGenomics services the needs of pathologists, oncologists, urologists and other physician specialists, academic institutions, and the pharmaceutical industry.
Investor Relations
Company Profile
Latest Quarterly Results
FY 2018
Fiscal Year Ended Dec 31, 2018
Latest 10-K
View Latest 10-KSign up for email alerts
Sign up todayNeoGenomics, Inc.
Nasdaq: NEO
Market/Symbol
Price
Change
Volume
Day Range
52 week Range
IR Contact Information
Investor Relations William Bonello
Chief Strategy and Corporate Development OfficerDirector, Investor Relations
T: (239) 690-4238
M: (239) 284-4314
bill.bonello@neogenomics.com
Transfer Agent Standard Registrar & Transfer Company
12528 South 1840 East
Draper, UT 84020
T: (801) 571-8844